OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

MOLECULAR PARTNERS N/  CH0256379097  /

SIX Swiss Exchange
9/26/2024  5:31:24 PM Chg. -0.0100 Volume Bid9:41:19 PM Ask9:41:19 PM Market Capitalization Dividend Y. P/E Ratio
4.0000CHF -0.25% 5,130
Turnover: 20,511.1550		 4.0000Bid Size: 25 4.2000Ask Size: 53 145.42 mill.CHF - -
GlobeNewswire 8/26 Molecular Partners Reports H1 2024 Corporate Highlights and Financials
GlobeNewswire 6/17 Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
GlobeNewswire 6/14 Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EH...
GlobeNewswire 6/11 Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPi...
GlobeNewswire 6/1 Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin)...
GlobeNewswire 5/16 Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional...
GlobeNewswire 4/29 Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supportin...
GlobeNewswire 4/19 Life Science Cares Launches in Switzerland
GlobeNewswire 4/17 Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
GlobeNewswire 3/26 Molecular Partners Publishes Invitation to Annual General Meeting 2024
GlobeNewswire 3/14 Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
GlobeNewswire 3/1 Molecular Partners Announces Dismissal of Class Action Lawsuit
GlobeNewswire 3/1 Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and ...
GlobeNewswire 1/7 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 1/5 Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
GlobeNewswire 12/14/2023 Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Co...
GlobeNewswire 12/10/2023 Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/...
GlobeNewswire 11/14/2023 Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summi...
GlobeNewswire 11/3/2023 Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) ...
GlobeNewswire 11/2/2023 Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with...
GlobeNewswire 11/1/2023 Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
GlobeNewswire 10/26/2023 Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin...
GlobeNewswire 9/13/2023 Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Ann...
GlobeNewswire 8/24/2023 Molecular Partners Reports H1 2023 Corporate Highlights and Financials
GlobeNewswire 3/24/2022 Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 ...